Metrika

  • citati u SCIndeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:5
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 5 od 53  
Back povratak na rezultate
2019, vol. 147, br. 3-4, str. 173-180
Hronična inflamacija i parametri lipidnog statusa kod gojaznih osoba sa normalnim i poremećenim metabolizmom glukoze
aKlinički centar Vojvodine, Klinika za endokrinologiju, dijabetes i bolesti metabolizma, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet
bUniverzitet u Novom Sadu, Fakultet tehničkih nauka
cKlinički centar Vojvodine, Klinika za ginekologiju i akušerstvo, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet
dKlinički centar Vojvodine, Klinika za neurologiju, Novi Sad + Univerzitet u Novom Sadu, Medicinski fakultet

e-adresaradoslavpejin@gmail.com
Ključne reči: C-reaktivni protein; lipoprotein (a); trigliceridi; metformin, gojaznost; dijabetes tipa 2
Sažetak
Uvod/Cilj U različitim stanjima sa povišenim stepenom hronične inflamacije, kao što su gojaznost i dijabetes, rane promene u metabolizmu lipida mogu predstavljati svrsishodan adaptivni odgovor u cilju smanjivanja inflamatorne reakcije u organizmu. Cilj istraživanja je bio da se ispita uticaj gojaznosti i glikozne regulacije na odnos hronične inflamacije i lipidskih parametara metabolizma. Metode Studija se sastojala od četiri grupe (n = 30 za svaku grupu): gojazne osobe sa poremećenim metabolizmom glukoze (subjekti sa novodijagnostikovanim dijabetesom melitusom tipa 2 (DMT2)) pre i u toku metforminske terapije, gojazne osobe sa normalnom tolerancijom glukoze (NTG) i kontrolne grupe zdravih subjekata normalne telesne mase. Odgovarajuća antropometrijska merenja i laboratorijska testiranja su sprovedena kod svih učesnika. Rezultati Između grupa gojaznih bolesnika povezanost nivoa visoko osetljivog C-reaktivnog proteina (hsCRP) sa nivoom triglicerida i lipoproteina (a) (Lp(a)) naročito je izražena u grupi osoba sa DMT2 pre početka terapije metforminom. U ovoj grupi nivo inflamacije je bio najviši i korelacioni koeficijenti triglicerida (r = 0,21 vs. r = -0,36; p = 0,0172) i Lp (a) (r = -0,17 vs. r = 0,36, p = 0,0324) sa hsCRP se statistički značajno razlikuju u poređenju sa grupom gojaznih. Linearne korelacije hsCRP sa trigliceridima (r = 0,21 vs. r = 0,38, p = 0,2449) i Lp(a) (r = -0,17 vs. r = -0,27, p = 0,3562) u grupama gojaznih osoba sa NTG i osoba sa DMT2 tokom terapije nisu se statistički značajno razlikovale. Tretman sa metforminom je promenio odnos linernih korelacija hsCRP sa trigliceridima i Lp(a) slično onome kod gojaznih osoba sa NTG. Zaključak Kod ispitanika sa novodijagnostikovanim DMT2, koji imaju najviši nivo zapaljenja, povećanje nivoa triglicerida može predstavljati deo antiinflamatornog odgovora, dok hipotetički molekuli Lp(a) mogu igrati ulogu u smanjenju povišenih nivoa inflamacije.
Reference
Abd, alamir M., Goyfman, M., Chaus, A., Dabbous, F., Tamura, L., Sandfort, V., Brown, A., Budoff, M. (2018) The Correlation of Dyslipidemia with the Extent of Coronary Artery Disease in the Multiethnic Study of Atherosclerosis. Journal of Lipids, 2018(): 1-9
Barcia, A.M., Harris, H.W. (2005) Triglyceride-Rich Lipoproteins as Agents of Innate Immunity. Clinical Infectious Diseases, 41(7):498-503
Bermúdez, V., Rojas, J., Salazar, J., Bello, L., Áñez, R., Toledo, A., Chacín, M., Aguirre, M., Villalobos, M., Chávez, M., Martínez, M.S., Torres, W., Torres, Y., Mejías, J. (2013) Variations of Lipoprotein(a) Levels in the Metabolic Syndrome: A Report from the Maracaibo City Metabolic Syndrome Prevalence Study. Journal of Diabetes Research, 2013(): 1-12
Chung, H.Y., Cesari, M., Anton, S., Marzetti, E., Giovannini, S., Seo, A.Y., Carter, C., Yu, B.P., Leeuwenburgh, C. (2009) Molecular inflammation: Underpinnings of aging and age-related diseases. Ageing Research Reviews, 8(1): 18-30
Elimam, H., Abdulla, A.M., Taha, I.M. (2019) Inflammatory markers and control of type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 13(1): 800-804
Ellis, K.L., Boffa, M.B., Sahebkar, A., Koschinsky, M.L., Watts, G.F. (2017) The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. Progress in Lipid Research, 68(): 57-82
Esteve, E., Ricart, W., Fernández-Real, J.M. (2005) Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clinical Nutrition, 24(1): 16-31
Fang, M., Qian, Q., Zhao, Z., Zhu, L., Su, J., Li, X. (2018) High-Sensitivity C-Reactive Protein Combined with Low-Density Lipoprotein Cholesterol as the Targets of Statin Therapy in Patients with Acute Coronary Syndrome. International Heart Journal, 59(2): 300-306
Katsiki, N., Al-Rasadi, K., Mikhailidis, D.P. (2017) Lipoprotein (a) and Cardiovascular Risk: The Show Must go on. Current Medicinal Chemistry, 24(10): 989-1006
Kimak, E., Zięba, B., Duma, D., Solski, J. (2018) Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease. Lipids in Health and Disease, 17(1): 71
Koley, S. (2018) Sur A. Association of lipid profile parameters with high sensitive C-reactive protein (hsCRP) in patients with dyslipidemia. Ann Med Health Sci Res., 8(1): 105-7
Lavanya, K., Ramamoorthi, K., Acharya, R.V., Madhyastha, S.P. (2017) Association between Overweight, Obesity in Relation to Serum Hs-CRP Levels in Adults 20-70 Years. Journal of Clinical and Diagnostic Research, 11(12):OC32-OC35
Müller, N., Schulte, D.M., Türk, K., Freitag-Wolf, S., Hampe, J., Zeuner, R., Schröder, J.O., Gouni-Berthold, I., Berthold, H.K., Krone, W., Rose-John, S., Schreiber, S., Laudes, M. (2015) IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. Journal of Lipid Research, 56(5): 1034-1042
Muñoz-Torrero, J.F.S., Rivas, D., Alonso, R., Crespo, L., Costo, A., Roman, M., Martín, C., Zamorano, J. (2012) Influence of Lipoprotein (a) on Inflammatory Biomarkers in Metabolic Syndrome. Southern Medical Journal, 105(7): 339-343
Orsó, E., Schmitz, G. (2017) Lipoprotein(a) and its role in inflammation, atherosclerosis and malignancies. Clinical Research in Cardiology Supplements, 12(S1): 31-37
Pagidipati, N.J., Hellkamp, A.S., Sharma, P.P., Wang, T.Y., Fonarow, G.C., Pencina, M. (2018) High-sensitivity C-reactive protein elevation in patients with prior myocardial infarction in the United States. American Heart Journal, 204(): 151-155
Peela, J.R., Latiwesh, O.B., Elshaari, F., Hussain, A., Tabrez, E., Viglianco, E., Edwards, A., Ali, F., Rawal, A.K. (2018) Investigating the Atherogenic Risk of Lipoprotein(a) in Type 2 Diabetic Patients. Cureus, 10(7):e3030
Penson, P.E., Long, D.L., Howard, G., Toth, P.P., Muntner, P., Howard, V.J., Safford, M.M., Jones, S.R., Martin, S.S., Mazidi, M., Catapano, A.L., Banach, M. (2018) Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. European Heart Journal, 39(40): 3641-3653
Ridker, P.M., Everett, B.M., Thuren, T., Macfadyen, J.G., Chang, W.H., Ballantyne, C., et al. (2017) CANTOS trial group antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med., 377: 1119-31
Saely, C. H., Koch, L., Schmid, F., Marte, T., Aczel, S., Langer, P., Hoefle, G., Drexel, H. (2006) Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients. European Journal of Clinical Investigation, 36(2): 91-97
Sendesni, R., Lahidheb, D., Ayoub, M., Grira, N., Lafi, D., Stambouli, N., Oudi, M.E., Ghazouani, E., Haouala, H., Aouni, Z., Mazigh, C. (2016) Correlation between Inflammatory Markers and Lipid Parameters in a Tunisian Coronary Artery Disease Group. OALib, 03(05): 1-9
Tang, Y., Liang, P., Chen, J., Fu, S., Liu, B., Feng, M., Lin, B., Lee, B., Xu, A., Lan, H.Y. (2018) The baseline levels and risk factors for high-sensitive C-reactive protein in Chinese healthy population. Immunity & Ageing, 15(1): 21
TopciuShufta, V., Haxhibeqiri, V., Begolli, L., BarutiGafurri, Z., Veseli, S., Haxhibeqiri, S., Miftari, R., Kurti, L., Avdiu, D. (2015) Correlation of Inflammation and Lipoprotein (a) with Hypercoagulability in Hemodialysis Patients. Medical Archives, 69(4): 232
Tsimikas, S. (2016) Lp(a) as a new target for reduction of risk of cardiovascular disease and emergenceof novel therapies to lower Lp(a). Current Opinion in Endocrinology & Diabetes and Obesity, 23(2): 157-164
Tsimikas, S., Clopton, P., Brilakis, E.S., Marcovina, S.M., Khera, A., Miller, E.R., de Lemos, J.A., Witztum, J.L. (2009) Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. Circulation, 119(13): 1711-1719
Ye, Z., Haycock, P. C., Gurdasani, D., Pomilla, C., Boekholdt, S. M., Tsimikas, S., Khaw, K.-T., Wareham, N. J., Sandhu, M. S., Forouhi, N. G. (2014) The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal?. Diabetes, 63(1): 332-342
 

O članku

jezik rada: engleski
vrsta rada: originalan članak
DOI: 10.2298/SARH180710017P
objavljen u SCIndeksu: 07.07.2019.